Johnson & Johnson, Novartis and Takeda returned to back the cancer and inflammatory drug developer and were joined by investors including AbbVie, Alphabet and Bristol Myers Squibb.

US-based oncology drug developer Ribon Therapeutics has secured $65m in funding from investors including internet and technology group Alphabet and pharmaceutical firms AbbVie, Bristol Myers Squibb, Johnson & Johnson, Novartis and Takeda.

Investment firm Deerfield Management and venture capital firm US Venture Partners (USVP) co-led the round, which included Avego BioScience Capital, Monashee Investment Management, Peregrine Ventures, Osage University Partners (OUP) and Column Group.

GV, AbbVie Ventures, Johnson & Johnson Innovation – JJDC, Novartis Venture Fund and Takeda Ventures represented…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn